RenovoRx, Inc. (Nasdaq: RNXT) announced today that the U.S. Patent and Trademark Office has issued patent NO. 12,290,564, titled "Methods for Treating Tumors," effective May 6, 2025. The patent expands intellectual property protection for the company's Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which utilizes the proprietary RenovoCath device for targeted cancer treatment.
Patent Strengthens Competitive Position
The newly issued patent covers innovative methods for treating tumors by delivering drugs locally to arterial regions near tumor sites after reducing microvasculature in the targeted area. Patent protection extends through November 2037, providing long-term commercial exclusivity for RenovoRx's targeted drug delivery approach.
"The issuance of this new patent highlights the innovation behind our TAMP therapy platform and strengthens our competitive position," said Shaun Bagai, CEO of RenovoRx. "This marks our ninth U.S. patent and 19th global patent which further expands our growing IP portfolio."
With this latest addition, RenovoRx now maintains a robust intellectual property portfolio comprising 19 issued patents and 12 pending patents worldwide. The expanding patent protection supports the company's ongoing commercialization efforts for RenovoCath, which received FDA clearance for isolation of blood flow and delivery of therapeutic agents to selected sites in the peripheral vascular system.
Commercial Momentum and Clinical Development
RenovoRx began generating revenue from RenovoCath device sales in December 2024, marking a significant commercial milestone. The company has received initial purchase orders from medical institutions, including several National Cancer Institute-designated centers, with some customers already placing repeat orders.
The strengthened IP portfolio also supports RenovoRx's ongoing Phase III clinical trial, TIGeR-PaC, which evaluates the investigational drug-device combination using intra-arterial gemcitabine (IAG) versus systemic chemotherapy for treating locally advanced pancreatic cancer (LAPC). The randomized, multi-center trial represents the company's lead investigational product candidate combining the TAMP therapy platform with the FDA-cleared RenovoCath device.
TAMP Technology Platform
The TAMP therapy platform is designed to deliver therapeutic agents directly across arterial walls near tumor sites, potentially minimizing systemic toxicities compared to traditional intravenous chemotherapy. RenovoCath enables temporary vessel occlusion for applications including arteriography, preoperative procedures, and chemotherapeutic drug infusion.
The combination of RenovoCath with gemcitabine has received Orphan Drug Designation from the FDA for both pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon potential new drug application approval.
Strategic Outlook
Bagai emphasized the patent's significance for the company's dual commercialization strategy: "Our robust IP portfolio is an essential asset as we advance and scale our commercialization of RenovoCath as a stand-alone device, which we began generating revenues in December of 2024."
RenovoRx continues exploring revenue-generating opportunities for its TAMP technology and RenovoCath device, either independently or through potential partnerships with medical device commercial partners. The company aims to expand adoption among medical institutions while advancing its clinical development programs for combination therapy applications.
The patent issuance reinforces RenovoRx's position in the targeted oncology therapy market, where the company addresses high unmet medical needs through innovative drug delivery solutions designed to improve safety, tolerance, and efficacy compared to conventional systemic treatments.
